Study title:
J Asthma. 2004;41(3):285-7. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. Gourgiotis D, Papadopoulos NG, Bossios A, Zamanis P, Saxoni-Papageorgiou PJ Asthma. 2004;41(3):285-7. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. Gourgiotis D, Papadopoulos NG, Bossios A, Zamanis P, Saxoni-Papageorgiou P
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Immune System Diseases
|
Brands: Please see report, Please see report, Please see report, Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PIDOTIMOD |
ATC code: L03AX05
|
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|